Stocks
Adamas Pharmaceuticals IncADMS
HealthcareBiotechnology
A specialty pharmaceutical company focused on developing and commercializing treatments for neurological disorders, with its lead product, GOCOVRI, approved for dyskinesia in Parkinson's disease patients. The company targets an underserved patient population and its commercial execution is closely watched by investors given the niche market opportunity.
Congressional Interest in Adamas Pharmaceuticals Inc (ADMS)
1 member of Congress has disclosed 1 trade in Adamas Pharmaceuticals Inc (ADMS), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading ADMS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-05-08 | MICHAEL T. MCCAUL | sell | $1K-$15K |